Pain-Related Neuropeptide Substance P May Drive Cancer Progression Through TLR-4 Activation
Substance P levels are elevated in cancer patients with pain and can upregulate TLR-4 in tumor cells, increasing proliferation, migration, and invasion — effects blocked by the NK-1R antagonist aprepitant.
Quick Facts
What This Study Found
Substance P was elevated in cancer patients with pain and upregulated TLR-4 expression in tumor cells via NK-1 receptors, increasing proliferation, migration, and invasion. Aprepitant blocked these effects.
Key Numbers
Substance P elevated in advanced cancer patients; SP promoted tumor growth and suppressed immunity via TLR-4 in vitro.
How They Did This
Serum samples from lung and breast cancer patients measured for substance P levels. Cell pharmacology experiments testing SP effects on TLR-4 expression, proliferation, migration, and invasion. Aprepitant (NK-1R blocker) used as a control.
Why This Research Matters
This provides a molecular mechanism linking chronic pain to worse cancer outcomes — not just reduced quality of life but actual tumor progression. It suggests that NK-1R antagonists like aprepitant could serve dual roles as anti-nausea and anti-cancer agents.
The Bigger Picture
The connection between pain and cancer progression has been observed clinically but poorly understood mechanistically. This substance P pathway provides a biological explanation and, importantly, a druggable target using an already-approved medication.
What This Study Doesn't Tell Us
In vitro experiments may not fully replicate in vivo tumor biology. Correlation between pain, SP levels, and cancer outcomes needs prospective clinical validation. Aprepitant's clinical anti-tumor efficacy hasn't been tested in trials.
Questions This Raises
- ?Could routine use of NK-1R antagonists in cancer patients reduce tumor progression alongside managing pain?
- ?Is substance P elevation specific to pain-related cancer progression or part of a broader inflammatory response?
- ?Would aprepitant or similar drugs improve outcomes in a clinical cancer trial?
Trust & Context
- Key Stat:
- TLR-4 receptor upregulated by substance P in tumor cells, increasing cancer aggressiveness
- Evidence Grade:
- Combines clinical observation (elevated SP in patients) with in vitro mechanistic evidence. Promising but requires clinical trial validation.
- Study Age:
- Published in 2020. The pain-cancer connection via neuropeptides remains an active research area.
- Original Title:
- Pain May Promote Tumor Progression via Substance P-Dependent Modulation of Toll-like Receptor-4.
- Published In:
- Pain medicine (Malden, Mass.), 21(12), 3443-3450 (2020)
- Authors:
- Yang, Chao, Sun, Yunheng, Ouyang, Xueyan, Li, Jing, Zhu, Zhen, Yu, Ruihua, Wang, Li, Jia, Lin, Ding, Gang, Wang, Yaosheng, Jiang, Feng
- Database ID:
- RPEP-05213
Evidence Hierarchy
Frequently Asked Questions
Can pain actually make cancer worse?
This study suggests yes — through substance P, a neuropeptide released during pain that can directly stimulate tumor cells to grow, spread, and become more invasive.
What is aprepitant used for currently?
Aprepitant (brand name Emend) is FDA-approved to prevent nausea and vomiting from chemotherapy. This study suggests it might also have direct anti-cancer effects by blocking substance P's action on tumors.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05213APA
Yang, Chao; Sun, Yunheng; Ouyang, Xueyan; Li, Jing; Zhu, Zhen; Yu, Ruihua; Wang, Li; Jia, Lin; Ding, Gang; Wang, Yaosheng; Jiang, Feng. (2020). Pain May Promote Tumor Progression via Substance P-Dependent Modulation of Toll-like Receptor-4.. Pain medicine (Malden, Mass.), 21(12), 3443-3450. https://doi.org/10.1093/pm/pnaa265
MLA
Yang, Chao, et al. "Pain May Promote Tumor Progression via Substance P-Dependent Modulation of Toll-like Receptor-4.." Pain medicine (Malden, 2020. https://doi.org/10.1093/pm/pnaa265
RethinkPeptides
RethinkPeptides Research Database. "Pain May Promote Tumor Progression via Substance P-Dependent..." RPEP-05213. Retrieved from https://rethinkpeptides.com/research/yang-2020-pain-may-promote-tumor
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.